On January 20, 2026, the U.S. Food and Drug Administration (FDA) convened a virtual meeting of the Tobacco Products Scientific Advisory Committee (TPSAC) to evaluate modified risk tobacco product (MRTP). The meeting focused on multiple ZYN nicotine pouch products, including flavours such as Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen, each proposed in 3 mg and 6 mg nicotine strengths.
During the open session, the Committee reviewed scientific evidence related to the relative health risks of the products, consumer understanding of the proposed modified risk claims, and the potential public health impact of granting a modified risk marketing order. TPSAC’s role is advisory, providing non-binding recommendations to the FDA to support regulatory decision-making under the U.S. tobacco control framework. Public comments were accepted through the FDA docket process ahead of the meeting, reflecting stakeholder engagement in the regulatory review of oral nicotine products.
Meeting details:
Date: January 22, 2026
Time: 9:00 a.m. - 4:30 p.m. ET

Consumer News Region
Consumer News Tags
United States; FDA; Tobacco Products Scientific Advisory Committee; ZYN nicotine pouches; Modified risk tobacco products; Swedish Match USA; Nicotine regulation; Public health review